Panelists discuss how ARNIs like sacubitril-valsartan provide superior outcomes compared with ACE inhibitors in HFrEF (20% reduction in cardiovascular events, 16% mortality reduction), with broad FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback